Button phentermine viagra xanax

Button phentermine viagra xanax

Matters on which we are required to report by exception We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion: •adequate accounting records have not been kept by the parent company, or returns adequate for our audit have not been received from branches not visited by us; or •the parent company financial statements are not in agreement with the accounting records and returns; or •certain disclosures of directors' remuneration specified by law are not made; or Tracey James Senior Statutory Auditor for and on behalf of Grant Thornton UK LLP Statutory Auditor, Chartered Accountants Bristol 20 March 2013 •we have not received all the information and explanations we require for our audit. Consolidated child cough hydrocodone Income Statement Note Year ended 31 December 2012 £000s Year ended 31 December 2011 £000s Revenue 3 44,897 45,957 Cost of sales (19,779) (21,469) Gross profit 25,118 24,488 Operating expenses Administration and marketing expense (11,856) (1 1,235] Amortisation of intangible assets (573) (735) Share-based employee remuneration 6 (369) (179) (12,798) (12,149) Operating profit 12,320 12,339 Finance costs Interest payable and similar charges 5 (1,541) (1,600) Interest income 5 - 2 Other finance income/(charges) 5 30 (29) (1,511) (1,627) Profit on ordinary activities before taxation 4 10,809 10,712 Taxation 7 (2,119) (2,076) Profit for the year attributable to equity shareholders 8,690 8,636 Earnings per share Basic (pence) 9 3.61 3.62 Diluted (pence) 9 3.40 3.39 26 All of the activities of the Group are classed as continuing. The accompanying accounting policies and notes button phentermine viagra xanax form an integral part of these financial statements. Consolidated Statement of Comprehensive Income Year ended 31 December 2012 £000s Year ended 31 December 2011 £000s Profit for the period 8,690 8,636 Interest rate swaps - cash flow hedge 6 22 Deferred tax on interest rate swaps (2) (button phentermine viagra xanax 6) Total comprehensive income for the period 8,694 8,button phentermine viagra xanax 652 Consolidated Balance Sheet Note 31 December 2012 £000s 31 December 2012 £000s 31 December 2011 £000s 31 December 2011 £000s 1 January 2011 £000s 1 January 2011 £000s Assets Non-current assets Intangible assets 10 79,890 66,130 60,287 Property, plant and equipment 11 564 765 888 80,454 66,895 61,175 Current assets Inventories 13 5,393 5,652 4,544 Trade and other receivables 14 10,145 8,660 9,690 Cash and cash equivalents 15 4,634 1,079 1,989 20,172 15,391 16,223 Total assets 100,626 82,286 77,398 Equity Ordinary share capital 25 2,430 2,401 2,361 Share premium account 25,297 24,866 24,331 Share option reserve 792 423 244 Reverse takeover reserve (329) (329) (329) Other reserve - (4) (20) Retained earnings 23,658 16,771 9,494 Total equity 51,848 44,128 36,081 Liabilities Non-current liabilities Long term financial liabilities 18 20,225 15,225 15,000 Convertible debt 18,19 - 4,460 4,822 Other liabilities 20 20 40 60 Derivative financial instruments 22 - - 13 Deferred tax liability 23 6,124 4,064 3,803 Provisions for other liabilities 24 364 510 641 26,733 24,299 24,339 Current liabilities Cash and cash equivalents 15 1 1 - Financial liabilities 18 6,250 4,250 4,001 Convertible debt 18,19 4,189 - - Corporation tax 1,322 1,046 721 Trade and other payables 17 10,086 8,367 11,869 Derivative financial instruments 22 - 6 15 Provisions for other liabilities 24 197 189 372 22,045 13,859 16,978 Total liabilities 48,778 38,158 41,317 Total equity and liabilities 100,626 82,286 77,398 The financial statements were approved by the Board of Directors on 20 March 2013. 28 John Dawson Richard Wright Director Director The accompanying accounting policies and notes form an integral part of these financial statements. Company number 04241478 Note 31 December 2012 £000s 31 December 2012 £000s 31 December 2011 £000s 31 December 2011 £000s 1 January 2011 £000s 1 January 2011 £000s Assets Non-current assets Investment in subsidiaries 12 37,618 36,402 32,260 Current assets Trade and other receivables Cash and cash equivalents 14 15 10,021 182 37,618 2,020 77 36,402 7,086 25 32,260 10,203 2,097 7,111 Total assets 47,821 38,499 39,371 Equity Ordinary share capital Share premium account Share option reserve Retained earnings 25 2,430 25,297 792 14,719 2,401 24,866 423 6,028 2,361 24,331 244 7,202 Total equity 43,238 33,718 34,138 Liabilities Non-current liabilities Convertible debt 18,19 4,460 4,822 - 4,460 4,822 Current liabilities Convertible debt Corporation tax Trade and other payables 18,19 17 4,189 4 390 321 95 316 4,583 321 411 Total liabilities 4,583 4,781 5,233 Total equity and liabilities 47,821 38,499 39,371 The financial statements were approved by the Board of Directors on 20 March 2013. 29 Financial Statements Company Balance Sheet John Dawson Richard Wright Director Director The accompanying accounting policies and notes form an integral part of these financial statements. Company number 04241478 Consolidated Statement of Changes in Equity Ordinary share capital £000s Share premium account £000s Share option reserve £000s Reverse takeover reserve £000s Other reserve £000s Retained earnings £000s Total equity £000s Balance 1 January 2011 2,361 24,331 244 (329) (20) 9,494 36,081 Issue of shares 40 535 - - - - 575 Dividend paid - - - - - (1,359) (1,359) Share options charge - - 179 - - - 179 Transactions with owners 40 535 179 - - (1,359) (605)button phentermine viagra xanax Profit for the period - - - - - 8,636 8,636 Other comprehensive income Interest rate swaps - cash flow hedge 22 22 Deferred tax on interest rate swaps - - - - (6) - (6) Total comprehensive income for the period - - - - 16 8,636 8,652 Balance 31 December combining adderal xanax 2011 2,401 24,866 423 (329) (4) 16,771 44,128 Balance 1 January 2012 2,401 24,866 423 (329) (4) 16,771 44,128 Issue of shares 29 431 - - - - 460 Dividend paid - - - - - (1,803) (1,803) Share options charge - - 369 - - - 369 Transactions with owners 29 431 369 - - (1,803) (974) Profit for the period - - - - - 8,690 8,690 Other comprehensive income Interest rate swaps - cash flow hedge 6 6 Deferred tax on interest rate swaps - - - - (2) - (2) Total comprehensive income for the period - - - - 4 8,690 8,694 Balance 31 December 2012 2,430 25,297 792 (329) - 23,658 51,848 The balance on the share premium account may not be legally distributed under section 831 of the Companies Act 2006.



Cloud phentermine viagra xanax
Buy xanax bars
Hydrocodone the easy way
Drug testing hydrocodone mg chemical powder
Hydrocodone buy purchase